Bausch Health expects to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D guidance
Bitget2026/10/12 10:49- Bausch Health flagged an increase to full-year 2026 adjusted EBITDA excluding acquired IPR&D guidance, based on preliminary third-quarter results.
- The update cited stronger business performance expectations for the rest of 2026, supported by prevailing foreign exchange rates.
- The company reported 13 consecutive quarters of year-over-year revenue growth and adjusted EBITDA growth, excluding Bausch + Lomb.
- More detail is expected with third-quarter results on Oct. 28.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
Crypto prices
More
